Cargando…
Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli
BACKGROUND AND AIM: Probiotics are beneficial microorganisms for humans and animals. In this study, we developed a microencapsulated probiotic with antibacterial activity against avian pathogenic Escherichia coli (APEC). MATERIALS AND METHODS: Alignment of the 16S rRNA sequences of the isolate WU222...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Veterinary World
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420709/ https://www.ncbi.nlm.nih.gov/pubmed/37576777 http://dx.doi.org/10.14202/vetworld.2023.1131-1140 |
_version_ | 1785088790199533568 |
---|---|
author | Mitsuwan, Watcharapong Saengsawang, Phirabhat Jeenkeawpieam, Juthatip Nissapatorn, Veeranoot Pereira, Maria de Lourdes Kitpipit, Warangkana Thomrongsuwannakij, Thotsapol Poothong, Saranporn Vimon, Sasi |
author_facet | Mitsuwan, Watcharapong Saengsawang, Phirabhat Jeenkeawpieam, Juthatip Nissapatorn, Veeranoot Pereira, Maria de Lourdes Kitpipit, Warangkana Thomrongsuwannakij, Thotsapol Poothong, Saranporn Vimon, Sasi |
author_sort | Mitsuwan, Watcharapong |
collection | PubMed |
description | BACKGROUND AND AIM: Probiotics are beneficial microorganisms for humans and animals. In this study, we developed a microencapsulated probiotic with antibacterial activity against avian pathogenic Escherichia coli (APEC). MATERIALS AND METHODS: Alignment of the 16S rRNA sequences of the isolate WU222001 with those deposited in GenBank revealed that the isolate was Pediococcus acidilactici with 99.6% homology. This bacterium was characterized as a probiotic based on its tolerance toward in vitro gastrointestinal tract (GIT) conditions, hydrophobicity, and auto-aggregation. The antibacterial activity of the probiotic’s culture supernatant against APEC was investigated using a broth microdilution assay. Pediococcus acidilactici was microencapsulated using sodium alginate and agar with diameters ranging from 47 to 61 μm. Then, physicochemical characteristics and stability of the microcapsules were determined. RESULTS: The isolate was characterized as a probiotic based on its resistance to low pH, bile salts, and pancreatin, with relative values of 79.2%, 70.95%, and 90.64%, respectively. Furthermore, the bacterium exhibited 79.56% auto-aggregation and 55.25% hydrophobicity at 24 h. The probiotic’s culture supernatant exhibited strong antibacterial activity against clinical APEC isolates with minimum inhibitory concentration and minimum bactericidal concentration of 12.5% and 25% v/v, respectively. Microencapsulation-enhanced bacterial viability in GIT compared to free cells. Moreover, 89.65% of the encapsulated cells were released into the simulated intestinal fluid within 4 h. The viable count in microcapsules was 63.19% after 3 months of storage at 4°C. CONCLUSION: The results indicated that the culture supernatant of P. acidilactici inhibited the growth of APEC. In addition, microencapsulation extends the viability of P. acidilactici under harsh conditions, indicating its potential application in the feed production. |
format | Online Article Text |
id | pubmed-10420709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Veterinary World |
record_format | MEDLINE/PubMed |
spelling | pubmed-104207092023-08-12 Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli Mitsuwan, Watcharapong Saengsawang, Phirabhat Jeenkeawpieam, Juthatip Nissapatorn, Veeranoot Pereira, Maria de Lourdes Kitpipit, Warangkana Thomrongsuwannakij, Thotsapol Poothong, Saranporn Vimon, Sasi Vet World Research Article BACKGROUND AND AIM: Probiotics are beneficial microorganisms for humans and animals. In this study, we developed a microencapsulated probiotic with antibacterial activity against avian pathogenic Escherichia coli (APEC). MATERIALS AND METHODS: Alignment of the 16S rRNA sequences of the isolate WU222001 with those deposited in GenBank revealed that the isolate was Pediococcus acidilactici with 99.6% homology. This bacterium was characterized as a probiotic based on its tolerance toward in vitro gastrointestinal tract (GIT) conditions, hydrophobicity, and auto-aggregation. The antibacterial activity of the probiotic’s culture supernatant against APEC was investigated using a broth microdilution assay. Pediococcus acidilactici was microencapsulated using sodium alginate and agar with diameters ranging from 47 to 61 μm. Then, physicochemical characteristics and stability of the microcapsules were determined. RESULTS: The isolate was characterized as a probiotic based on its resistance to low pH, bile salts, and pancreatin, with relative values of 79.2%, 70.95%, and 90.64%, respectively. Furthermore, the bacterium exhibited 79.56% auto-aggregation and 55.25% hydrophobicity at 24 h. The probiotic’s culture supernatant exhibited strong antibacterial activity against clinical APEC isolates with minimum inhibitory concentration and minimum bactericidal concentration of 12.5% and 25% v/v, respectively. Microencapsulation-enhanced bacterial viability in GIT compared to free cells. Moreover, 89.65% of the encapsulated cells were released into the simulated intestinal fluid within 4 h. The viable count in microcapsules was 63.19% after 3 months of storage at 4°C. CONCLUSION: The results indicated that the culture supernatant of P. acidilactici inhibited the growth of APEC. In addition, microencapsulation extends the viability of P. acidilactici under harsh conditions, indicating its potential application in the feed production. Veterinary World 2023-05 2023-05-30 /pmc/articles/PMC10420709/ /pubmed/37576777 http://dx.doi.org/10.14202/vetworld.2023.1131-1140 Text en Copyright: © Mitsuwan, et al. https://creativecommons.org/licenses/by/4.0/Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Mitsuwan, Watcharapong Saengsawang, Phirabhat Jeenkeawpieam, Juthatip Nissapatorn, Veeranoot Pereira, Maria de Lourdes Kitpipit, Warangkana Thomrongsuwannakij, Thotsapol Poothong, Saranporn Vimon, Sasi Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli |
title | Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli |
title_full | Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli |
title_fullStr | Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli |
title_full_unstemmed | Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli |
title_short | Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli |
title_sort | development of a microencapsulated probiotic containing pediococcus acidilactici wu222001 against avian pathogenic escherichia coli |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420709/ https://www.ncbi.nlm.nih.gov/pubmed/37576777 http://dx.doi.org/10.14202/vetworld.2023.1131-1140 |
work_keys_str_mv | AT mitsuwanwatcharapong developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli AT saengsawangphirabhat developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli AT jeenkeawpieamjuthatip developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli AT nissapatornveeranoot developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli AT pereiramariadelourdes developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli AT kitpipitwarangkana developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli AT thomrongsuwannakijthotsapol developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli AT poothongsaranporn developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli AT vimonsasi developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli |